Trial Profile
Pharmacoeconomic outcomes of levalbuterol [levosalbutamol] and racemic albuterol [salbutamol] in inpatients requiring nebulization (POLARIS).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Levosalbutamol (Primary) ; Salbutamol
- Indications Acute asthma; Asthma; Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms POLARIS
- Sponsors Sumitomo Pharma America
- 01 Sep 2008 Results were reported in Clinical Therapeutics.
- 19 May 2008 New trial record.